Ratings by William Blair (Andrew Brackmann)
| Date | Company | Symbol | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 5/14/2026 | MDxHealth SA | MDXH | Downgrade | Market Perform (Outperform) |
1.95 (0.19) |
-90.26% | Details | |
| 3/16/2026 | Neogenomics | NEO | Maintain | Market Perform (N/A) |
|
Details | ||
| 3/10/2026 | Exagen | XGN | Maintain | Outperform (N/A) |
|
Details | ||
| 2/27/2026 | Biodesix | BDSX | Upgrade | Outperform (Market Perform) |
12.93 (21.26) |
64.42% | Details | |
| 1/12/2026 | Exagen | XGN | Maintain | Outperform (N/A) |
|
Details | ||
| 12/9/2025 | Owlet Inc. | OWLT | New Coverage | Outperform (N/A) |
14.59 (4.03) |
-72.38% | Details | |
| 12/1/2025 | BillionToOne Inc | BLLN | New Coverage | Outperform (N/A) |
130.18 (111.47) |
-14.37% | Details | |
| 11/21/2025 | Exact Sciences | EXAS | Downgrade | Market Perform (Outperform) |
86.18 (104.91) |
21.73% | Details | |
| 11/19/2025 | Exact Sciences | EXAS | Maintain | Outperform (N/A) |
|
Details | ||
| 8/26/2025 | CareDx, Inc | CDNA | New Coverage | Market Perform (N/A) |
12.97 (69.10) |
432.77% | Details | |
| 8/7/2025 | Veracyte, Inc | VCYT | Maintain | Outperform (N/A) |
|
Details | ||
| 7/29/2025 | Neogenomics | NEO | Downgrade | Market Perform (Outperform) |
6.46 (16.69) |
158.36% | Details | |
| 7/10/2025 | Exact Sciences | EXAS | Maintain | Outperform (N/A) |
|
Details | ||
| 3/17/2025 | Butterfly Network | BFLY | New Coverage | Outperform (N/A) |
2.68 (6.66) |
148.51% | Details | |
| 10/1/2024 | Aldeyra Therapeutics | ALDX | Maintain | Outperform (N/A) |
|
Details | ||
| 2/14/2024 | Quidel Corp. | QDEL | Downgrade | Market Perform (Outperform) |
66.77 (13.77) |
-79.38% | Details | |
| 9/12/2023 | Sight Sciences Inc. | SGHT | Downgrade | Market Perform (Outperform) |
6.14 (6.15) |
0.16% | Details | |
| 3/24/2023 | MDxHealth SA | MDXH | New Coverage | Outperform (N/A) |
2.86 (1.95) |
-31.82% | Details | |
| 11/4/2022 | DermTech Inc. | DMTK | Downgrade | Market Perform (Outperform) |
3.00 (0.09) |
-97% | Details | |
| 2/3/2022 | Sight Sciences Inc. | SGHT | New Coverage | Outperform (N/A) |
14.94 (9.02) |
-39.63% | Details |
